Interferon kappa
An interferon produced by human keratinocytes.
General information
Interferon kappa is a type I interferone produced by human keratinocytes that induces antiviral response (LaFleur et al., 2001).
Interferon kappa on DrugBank
Interferon kappa on Wikipedia
Synonyms
IFN-κ
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19
Protein factor Non-randomized controlled open trial Moderate severity |
Patients | Administration in an aerosol formulation with TFF2 was safe and resulted in clinical improvement. Sample size: 11 + 22 control. Dosage: 1-2 mg (one million U/mg) IFN-κ and 5 mg TFF2, 3 times every 48 hours. Endpoints: The time to discharge from the hospital, improvement in CT imaging, resolution of cough, and the rate of negative viral RNA after 10 days of treatment. |
Jul/29/2020 | |
|
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
Protein factor Randomized controlled open trial Moderate severity |
Patients | Combined therapy with trefoil factor 2. Significantly shortened time of viral RNA negative conversion and time until improvement assessed by CT imaging. The treatment was safe. Sample size: 40 + 40 control. Dosage: 2 mg in aerosol inhalation once daily for 6 days. |
Sep/20/2020 |
